Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.
Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. Huo L, et al. Among authors: alvarez rh. Mod Pathol. 2016 Apr;29(4):330-46. doi: 10.1038/modpathol.2016.38. Epub 2016 Feb 26. Mod Pathol. 2016. PMID: 26916073 Free article.
Inflammatory breast cancer: what we know and what we need to learn.
Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Yamauchi H, et al. Among authors: alvarez rh. Oncologist. 2012;17(7):891-9. doi: 10.1634/theoncologist.2012-0039. Epub 2012 May 14. Oncologist. 2012. PMID: 22584436 Free PMC article. Review.
High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. Anfossi S, et al. Among authors: alvarez rh. PLoS One. 2014 Jan 8;9(1):e83113. doi: 10.1371/journal.pone.0083113. eCollection 2014. PLoS One. 2014. PMID: 24416156 Free PMC article.
Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Mego M, et al. Among authors: alvarez rh. Breast Cancer Res. 2015 Jan 9;17(1):2. doi: 10.1186/s13058-014-0507-6. Breast Cancer Res. 2015. PMID: 25572591 Free PMC article.
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Fouad TM, et al. Among authors: alvarez rh. Breast Cancer Res Treat. 2015 Jul;152(2):407-16. doi: 10.1007/s10549-015-3436-x. Epub 2015 May 29. Breast Cancer Res Treat. 2015. PMID: 26017070 Free PMC article.
Identification of frequent somatic mutations in inflammatory breast cancer.
Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Matsuda N, et al. Among authors: alvarez rh. Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27. Breast Cancer Res Treat. 2017. PMID: 28243898
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer.
Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Ding Q, et al. Among authors: alvarez rh. Hum Pathol. 2018 Jul;77:121-129. doi: 10.1016/j.humpath.2018.04.002. Epub 2018 Apr 22. Hum Pathol. 2018. PMID: 29689244
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Giuliano M, et al. Among authors: alvarez rh. Breast Cancer Res. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907. Breast Cancer Res. 2011. PMID: 21699723 Free PMC article.
Metastasis in the breast mimicking inflammatory breast cancer.
Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V. Alvarez RH, et al. J Clin Oncol. 2012 Aug 1;30(22):e202-6. doi: 10.1200/JCO.2011.40.2230. Epub 2012 Jun 25. J Clin Oncol. 2012. PMID: 22734030 No abstract available.
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Giordano A, et al. Among authors: alvarez rh. Mol Cancer Ther. 2012 Nov;11(11):2526-34. doi: 10.1158/1535-7163.MCT-12-0460. Epub 2012 Sep 12. Mol Cancer Ther. 2012. PMID: 22973057 Free PMC article.
70 results